Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that, as an increasing number of drugs are developed to treat multiple conditions and risk factors, pharmaceutical companies need to achieve a better understanding of overlapping and comorbid patient populations. Totaling more than $30 billion, the metabolic syndrome drug market, which includes type 2 diabetes, obesity, dyslipidemia, and hypertension, is an example of such a comorbid patient population that offers huge commercial opportunity.

To assist organizations in identifying the prevalent population of metabolic syndrome sufferers in the United States, Decision Resources introduces the Metabolic Syndrome Patient Comorbidity Group. The Metabolic Syndrome Patient Comorbidity Group is a comprehensive database that is easily manipulated to create epidemiological projections of key patient segments for metabolic syndrome.

"Biopharmaceutical companies can use this information to build accurate market forecasts, identify patient subgroups by metabolic risk factors, and analyze overlaps of subgroup populations," said Dr. Michael McGuill, director of epidemiology at Decision Resources.

Decision Resources' new Metabolic Syndrome Patient Comorbidity Group allows users to:

  * Group diseases and/or risk factors based on related diseases and drugs     to treat them.   * Find the number of prevalent cases in the United States of each     combination of three or more conditions that make up metabolic     syndrome.   * Summarize possible trends in the prevalence of metabolic syndrome and     its components over a ten-year forecast period.   * Define exact patient comorbidity groups and overlaps.  

Data for the Metabolic Syndrome Patient Comorbidity Group are generated using the National Health and Nutrition Examination Survey (NHANES III and NHANES 1999-2000) data.

About Decision Resources

Decision Resources, Inc., ( is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563,

Physicians at Odds Over the Advantages of Fixed-Dose Statin Combination Therapies for the Treatment of Post-Myocardial Infarction

View Now